FDA OKs Subcutaneous Vedolizumab for UC Maintenance Therapy FDA OKs Subcutaneous Vedolizumab for UC Maintenance Therapy

Takeda expects subcutaneous vedolizumab for UC maintenance therapy to be available in the United States as a single-dose pre-filled pen (Entyvio Pen) by the end of October.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology News Alert Source Type: news